ImmunityBio Inc. (NASDAQ:IBRX) has a beta value of 1.79 and has seen 1.57 million shares traded in the last trading session. The company, currently valued at $2.43B, closed the last trade at $6.14 per share which meant it lost -$0.12 on the day or -1.92% during that session. The IBRX stock price is -639.74% off its 52-week high price of $45.42 and 16.78% above the 52-week low of $5.11. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.3 million shares traded. The 3-month trading volume is 1.48 million shares.
The consensus among analysts is that ImmunityBio Inc. (IBRX) is a Buy stock at the moment, with a recommendation rating of 2.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.21.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Sporting -1.92% in the red in last session, the stock has traded in the red over the last five days, with the highest price hit on Monday, 01/10/22 when the IBRX stock price touched $6.14 or saw a rise of 20.26%. Year-to-date, ImmunityBio Inc. shares have moved 0.99%, while the 5-day performance has seen it change -18.46%. Over the past 30 days, the shares of ImmunityBio Inc. (NASDAQ:IBRX) have changed 3.72%. Short interest in the company has seen 10.43 million shares shorted with days to cover at 6.11.
Wall Street analysts have a consensus price target for the stock at $20.00, which means that the shares’ value could jump 69.3% from current levels. The projected low price target is $20.00 while the price target rests at a high of $20.00. In that case, then, we find that the current price level is -225.73% off the targeted high while a plunge would see the stock gain -225.73% from current levels.
ImmunityBio Inc. (IBRX) estimates and forecasts
The company’s shares have lost -47.74% over the past 6 months, compared to 7.80% for the industry. Revenue growth from the last financial year stood is estimated to be 413.50%.
1 analysts offering their estimates for the company have set an average revenue estimate of $20k for the current quarter. 1 have an estimated revenue figure of $20k for the next quarter concluding in Mar 2022. Year-ago sales stood $21k and $139k respectively for this quarter and the next, and analysts expect sales will shrink by -4.80% for the current quarter and -85.60% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 23.10% over the past 5 years. Earnings growth for 2022 is a modest -27.80% while over the next 5 years, the company’s earnings are expected to decrease by -1.70%.
ImmunityBio Inc. is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
ImmunityBio Inc. (NASDAQ:IBRX)’s Major holders
Insiders own 79.65% of the company shares, while shares held by institutions stand at 8.31% with a share float percentage of 40.84%. Investors are also buoyed by the number of investors in a company, with ImmunityBio Inc. having a total of 197 institutions that hold shares in the company. The top two institutional holders are Vanguard Group, Inc. (The) with over 7.03 million shares worth more than $68.48 million. As of Sep 29, 2021, Vanguard Group, Inc. (The) held 1.77% of shares outstanding.
The other major institutional holder is Blackrock Inc., with the holding of over 5.55 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $54.07 million and represent 1.40% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. As of Sep 29, 2021, the former fund manager holds about 1.01% shares in the company for having 4.02 million shares of worth $39.15 million while later fund manager owns 2.23 million shares of worth $21.74 million as of Sep 29, 2021, which makes it owner of about 0.56% of company’s outstanding stock.